Radient Pharmaceuticals Corporation (OTCQX: RXPC) (PINK: RXPC) reached up 10.53% in morning trading to $.0042 with 30M shares traded. Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. Radient Pharmaceuticals Corporation (OTCQX: RXPC.PK - News) (Pinksheets: RXPC.PK - News) today announced it has filed for patent protection for its proprietary Onko-Sure® cancer test in Australia and New Zealand.
Tactical Air Defense Services, Inc. (OTCBB:TADF) reached up 12.50% in morning trading to $.0018 with 7M shares traded. Tactical Air Defense Services, Inc. is an Aerospace/Defense Services contractor that offers tactical aviation services, aerial refueling, aircraft maintenance, and other Aerospace/Defense services to the United States and Foreign militaries and agencies. Tactical Air Defense Services, Inc. (OTCBB:TADF.PK - News) announced that its Embraer 314 Super Tucano aircraft (the "Super Tucano") that it acquired on lease through a joint-venture Services Agreement (the "Agreement") with Tactical Air Support, Inc. ("Tac-Air"), is finally delivered and flying.
Bioheart, Inc. (OTCBB:BHRT) reached up 11.11% in morning trading to $.08 with 1M shares traded. Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart, Inc. (OTCBB:BHRT.OB - News) announced that they will begin a US clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the FDA to begin a Phase I study in the US.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
